Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Resuscitation and endoscopy in upper-GI bleeding

Essential points for quick revision.

Saved on this device
!
Ongoing haematemesis with shock

Active upper-GI haemorrhage can cause airway contamination, rapid circulatory collapse and cardiac ischaemia before a laboratory haemoglobin reflects the loss.

Action: Summon senior, anaesthetic, transfusion and endoscopy support, position and suction the airway, obtain large-bore access, activate major-haemorrhage treatment when indicated and proceed to endoscopy after optimal resuscitation.

Synopsis

Resuscitate acute upper-GI haemorrhage, protect the airway, use blood components proportionately, deliver endoscopy at the correct time and prevent rebleeding after endoscopic haemostasis.

  • Begin with ABCDE, suction, two large-bore intravenous lines, full blood count, coagulation, renal profile, lactate and group-and-save or crossmatch according to severity.
  • Use the local massive-haemorrhage protocol for massive bleeding; outside major haemorrhage or acute coronary syndrome, NICE supports a restrictive red-cell threshold of 70 g/L with a 70–90 g/L target.
  • NICE: unstable severe bleeding needs immediate endoscopy after optimal resuscitation, other admissions within 24 hours, and no pre-endoscopy acid suppression. ESGE 2026: generally endoscopy within 24 hours unless instability persists despite adequate resuscitation, and consider pre-endoscopy high-dose IV PPI without delaying the procedure.

Key red flags

Reduced consciousness or continuing high-volume haematemesis requires early airway planning because emergency endoscopy cannot be performed safely through an unprotected contaminated airway.

Persistent hypotension, rising lactate or recurrent bleeding after initial haemostasis should prompt repeat endoscopy or urgent radiological or surgical control, not repeated crystalloid alone.

Threatened airway

Ongoing haematemesis, impaired consciousness or hypoxaemia predicts aspiration and difficult emergency endoscopy.

Haemorrhagic shock

Hypotension, tachycardia, cool peripheries, confusion, oliguria and rising lactate indicate inadequate tissue perfusion.

Reasoning priorities

01
Serial ABCDE and venous lactate

Measure immediate airway, respiratory and perfusion response.

A falling pressure or rising lactate despite fluid and blood suggests ongoing haemorrhage and need for faster control.

Worked reasoning

Worked case: shock to durable haemostasisResuscitate, treat and verify control

A 66-year-old has repeated red haematemesis, pulse 126, systolic pressure 82 mmHg and reduced peripheral perfusion while taking naproxen.

  1. Call anaesthetic, gastroenterology and transfusion support, use suction and airway positioning, obtain two large-bore lines and start protocolled haemorrhage resuscitation; pressure improves to 108 mmHg and mental state normalises.
  2. Under the NICE unstable-bleeding pathway, perform endoscopy within two hours of optimal resuscitation: a posterior duodenal ulcer has a Forrest IIa non-bleeding visible vessel, so treatment is indicated. The ulcer action map is Ia/Ib active bleeding and IIa vessel: haemostasis; IIb adherent clot: expert clot removal and underlying treatment; IIc flat spot or III clean base: no haemostatic endotherapy.
  3. Apply a mechanical clip to the ulcer vessel and confirm that haemostasis is achieved; a non-bleeding vessel does not require injection, clipping and thermal treatment all together. Start esomeprazole 80 mg IV over 30 minutes followed immediately by 8 mg/hour for 71.5 hours, with renal, hepatic and interaction checks.
  4. Control persists through 72 hours: there is no fresh haematemesis, pulse stays below 90 and haemoglobin stabilises without further transfusion. With normal hepatic function and a reliable oral route, change to Nexium 40 mg orally once daily for four weeks, swallowed whole with water. The H pylori and NSAID prevention plans and a rebleeding contact route are documented before discharge.
Stable admitted bleedMeet the 24-hour window

A patient with melaena is normotensive after assessment and has no ongoing haematemesis but requires hospital admission.

Key medicines

Esomeprazole after therapeutic endoscopy for bleeding ulcerAfter therapeutic endoscopy for acute bleeding from a gastric or duodenal ulcer, infuse esomeprazole 80 mg IV over 30 minutes, then 8 mg/hour IV continuously for 71.5 hours: 72 hours total. Follow with oral Nexium 40 mg once daily for four weeks, using its separate gastro-resistant tablet licence for prolonged treatment after IV prevention of ulcer rebleeding. Swallow the tablet whole with liquid; do not chew or crush it. The IV label requires oral follow-on treatment, while the oral label supplies this dose and duration.Do not delay resuscitation or endoscopic haemostasis. In severe hepatic impairment, after the initial 80 mg IV, 4 mg/hour for 71.5 hours may be sufficient; oral Nexium must not exceed 20 mg daily, requiring the appropriate lower-strength product rather than the 40 mg tablet. Renal impairment needs no dose adjustment, but severe renal insufficiency warrants caution. Contraindications include benzimidazole/product hypersensitivity and concomitant nelfinavir. Concomitant clopidogrel is discouraged; review interacting medicines, including high-dose methotrexate. Longer use warrants magnesium and B12 risk review. Continuing bleeding requires renewed source control, not escalation of PPI alone.
Open full textbook Answer 2 questions
Sources and review status7 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom